Singh Akhilendra, Kanwar Amrinder Jit, Parsad Davinder, Mahajan Rahul
Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):29-35. doi: 10.4103/0378-6323.125479.
Oral minocycline has been recently shown to halt disease progression in active vitiligo.
The present study was planned to compare the efficacy and tolerability of oral minocycline with oral mini pulse (OMP) corticosteroids in active vitiligo.
A total of 50 patients with actively spreading vitiligo were randomized to receive either minocycline 100 mg/day (Group I-25 patients) or OMP 2.5 mg dexamethasone on 2 consecutive days in a week (Group II-25 patients) for 6 months. These were followed-up at every 2 weeks interval. Mean vitiligo disease activity score (VIDA) and mean Vitiligo Area Scoring Index (VASI) were assessed in all patients in addition to the photographic comparison before and after treatment.
Both groups showed a significant decrease in VIDA from 4.0 to 1.64±0.86 (P<0.001) in Group I and from 4.0 to 1.68±0.69 (P<0.001) in Group II. However, the difference between the mean VIDA scores in the two groups was not statistically significant (P=0.60) at the end of treatment period. The mean VASI declined from 1.71±1.45 to 1.52±1.43 Group I (P=0.06) and from 1.39±1.31 to 1.17±1.34 in Group II (P=0.05). The difference between VASI in Group I and II was not significant at the end of 24 weeks of treatment (P=0.11).
Both dexamethasone OMP and oral minocycline are effective drugs for managing the arrest of disease activity in vitiligo.
近期研究表明口服米诺环素可阻止活动性白癜风的疾病进展。
本研究旨在比较口服米诺环素与口服小剂量脉冲(OMP)皮质类固醇治疗活动性白癜风的疗效和耐受性。
总共50例活动性白癜风患者被随机分为两组,一组25例患者接受每日100mg米诺环素治疗(第一组),另一组25例患者每周连续2天接受2.5mg地塞米松的OMP治疗(第二组),疗程6个月。每2周进行一次随访。除了治疗前后的照片对比外,还对所有患者评估了白癜风疾病活动度平均评分(VIDA)和白癜风面积评分指数(VASI)。
两组的VIDA均显著下降,第一组从4.0降至1.64±0.86(P<0.001),第二组从4.0降至1.68±0.69(P<0.001)。然而,在治疗期末,两组的平均VIDA评分差异无统计学意义(P=0.60)。第一组的平均VASI从1.71±1.45降至1.52±1.43(P=0.06),第二组从1.39±1.31降至1.17±1.34(P=0.05)。治疗24周结束时,第一组和第二组的VASI差异无统计学意义(P=0.11)。
地塞米松OMP和口服米诺环素都是控制白癜风疾病活动的有效药物。